Cargando…

Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy

Medulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhen-Yu, Xu, Jian, Ren, Yong, Yao, Yu, Li, Kay Ka-Wai, Ng, Ho-Keung, Mao, Ying, Zhou, Liang-Fu, Zhong, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059646/
https://www.ncbi.nlm.nih.gov/pubmed/24932704
http://dx.doi.org/10.1371/journal.pone.0099490
_version_ 1782321262102577152
author Zhang, Zhen-Yu
Xu, Jian
Ren, Yong
Yao, Yu
Li, Kay Ka-Wai
Ng, Ho-Keung
Mao, Ying
Zhou, Liang-Fu
Zhong, Ping
author_facet Zhang, Zhen-Yu
Xu, Jian
Ren, Yong
Yao, Yu
Li, Kay Ka-Wai
Ng, Ho-Keung
Mao, Ying
Zhou, Liang-Fu
Zhong, Ping
author_sort Zhang, Zhen-Yu
collection PubMed
description Medulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (CHT) is still limited. The authors performed a retrospective study of 173 medulloblastoma patients treated at two institutions from 2002 to 2011. Formalin-fixed paraffin embedded (FFPE) tissues were available in all the cases and sections were stained to classify histological and molecular subgroups. Univariate and multivariate analyses were used to investigate prognostic factors. Of 173 patients, there were 118 children and 55 adults, 112 males and 61 females. Estimated 5-year overall survival (OS) rates for all patients, children and adults were 52%, 48% and 63%, respectively. After multivariate analysis, postoperative primary radiation therapy (RT) and chemotherapy (CHT) were revealed as favorable prognostic factors influencing OS and EFS. Postoperative primary chemotherapy (CHT) was found significantly improving the survival of children (p<0.001) while it was not a significant prognostic factor for adult patients. Moreover, patients in WNT subtype had better OS (p = 0.028) than others (SHH and Non-SHH/WNT subtypes) given postoperative adjuvant therapies. Postoperative primary RT was found to be a strong prognostic factor influencing the survival in all histological and molecular subgroups (p<0.001). Postoperative primary CHT was found significantly to influence the survival of classic medulloblastoma (CMB) (OS p<0.001, EFS p<0.001), SHH subgroup (OS p = 0.020, EFS p = 0.049) and WNT subgroup (OS p = 0.003, EFS p = 0.016) but not in desmoplastic/nodular medulloblastoma (DMB) (OS p = 0.361, EFS p = 0.834) and Non-SHH/WNT subgroup (OS p = 0.127, EFS p = 0.055). Our study showed postoperative primary CHT significantly influence the survival of CMB, SHH subgroup and WNT subgroup but not in DMB and Non-SHH/WNT subgroup of MB.
format Online
Article
Text
id pubmed-4059646
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40596462014-06-19 Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy Zhang, Zhen-Yu Xu, Jian Ren, Yong Yao, Yu Li, Kay Ka-Wai Ng, Ho-Keung Mao, Ying Zhou, Liang-Fu Zhong, Ping PLoS One Research Article Medulloblastoma (MB) is one of the most common primary central nervous system tumors in children. Data is lacking of a large cohort of medulloblastoma patients in China. Also, our knowledge on the sensitivity of different molecular subgroups of MB to adjuvant radiation therapy (RT) or chemotherapy (CHT) is still limited. The authors performed a retrospective study of 173 medulloblastoma patients treated at two institutions from 2002 to 2011. Formalin-fixed paraffin embedded (FFPE) tissues were available in all the cases and sections were stained to classify histological and molecular subgroups. Univariate and multivariate analyses were used to investigate prognostic factors. Of 173 patients, there were 118 children and 55 adults, 112 males and 61 females. Estimated 5-year overall survival (OS) rates for all patients, children and adults were 52%, 48% and 63%, respectively. After multivariate analysis, postoperative primary radiation therapy (RT) and chemotherapy (CHT) were revealed as favorable prognostic factors influencing OS and EFS. Postoperative primary chemotherapy (CHT) was found significantly improving the survival of children (p<0.001) while it was not a significant prognostic factor for adult patients. Moreover, patients in WNT subtype had better OS (p = 0.028) than others (SHH and Non-SHH/WNT subtypes) given postoperative adjuvant therapies. Postoperative primary RT was found to be a strong prognostic factor influencing the survival in all histological and molecular subgroups (p<0.001). Postoperative primary CHT was found significantly to influence the survival of classic medulloblastoma (CMB) (OS p<0.001, EFS p<0.001), SHH subgroup (OS p = 0.020, EFS p = 0.049) and WNT subgroup (OS p = 0.003, EFS p = 0.016) but not in desmoplastic/nodular medulloblastoma (DMB) (OS p = 0.361, EFS p = 0.834) and Non-SHH/WNT subgroup (OS p = 0.127, EFS p = 0.055). Our study showed postoperative primary CHT significantly influence the survival of CMB, SHH subgroup and WNT subgroup but not in DMB and Non-SHH/WNT subgroup of MB. Public Library of Science 2014-06-16 /pmc/articles/PMC4059646/ /pubmed/24932704 http://dx.doi.org/10.1371/journal.pone.0099490 Text en © 2014 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhang, Zhen-Yu
Xu, Jian
Ren, Yong
Yao, Yu
Li, Kay Ka-Wai
Ng, Ho-Keung
Mao, Ying
Zhou, Liang-Fu
Zhong, Ping
Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
title Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
title_full Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
title_fullStr Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
title_full_unstemmed Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
title_short Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
title_sort medulloblastoma in china: clinicopathologic analyses of shh, wnt, and non-shh/wnt molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059646/
https://www.ncbi.nlm.nih.gov/pubmed/24932704
http://dx.doi.org/10.1371/journal.pone.0099490
work_keys_str_mv AT zhangzhenyu medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT xujian medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT renyong medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT yaoyu medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT likaykawai medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT nghokeung medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT maoying medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT zhouliangfu medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy
AT zhongping medulloblastomainchinaclinicopathologicanalysesofshhwntandnonshhwntmolecularsubgroupsrevealdifferenttherapeuticresponsestoadjuvantchemotherapy